Nektar Therapeutics Stock Price and Value Analysis

Should you buy Nektar Therapeutics stock? (NasdaqGS:NKTR). Let's see how it does in our automated value investing analysis system.

NKTR Free Cash Flow Trend

Free Cash Flow trendline for NKTR
Free Cash Flow trendline for Nektar Therapeutics

Hmm, we can't give any reliable projection for Nektar Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company is solid.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company is not making money.
  • This company pays no dividend.

Inside the NKTR Numbers

NKTR Price
(Nektar Therapeutics stock price per share)
[?] PE Ratio versus Sector 60% lower than other Healthcare stocks
[?] PE Ratio versus Industry 86% lower than other Biotechnology stocks
[?] Cash Yield -2.28%
[?] Free Cash Flow Jitter 45%

Is Nektar Therapeutics Stock on Sale?

Based on our analysis, we believe that you should not buy Nektar Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy NKTR Stock?

Does Nektar Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.